University of Nice Sophia-Antipolis, Valbonne, France.
Mucosal Immunol. 2011 Jan;4(1):53-65. doi: 10.1038/mi.2010.51. Epub 2010 Sep 1.
The prevalence of asthma has steadily increased during the last decade, probably as the result of changes in the environment, including reduced microbial exposure during infancy. Accordingly, experimental studies have shown that deliberate infections with live pathogens prevent the development of allergic airway diseases in mice. Bacterial extracts are currently used in children suffering from repeated upper respiratory tract infections. In the present study, we have investigated whether bacterial extracts, commercially available as Broncho-Vaxom (BV), could prevent allergic airway disease in mice. Oral treatment with BV suppressed airway inflammation through interleukin-10 (IL-10)-dependent and MyD88 (myeloid differentiation primary response gene (88))-dependent mechanisms and induced the conversion of FoxP3 (forkhead box P3)(-) T cells into FoxP3(+) regulatory T cells. Furthermore, CD4(+) T cells purified from the trachea of BV-treated mice conferred protection against airway inflammation when adoptively transferred into sensitized mice. Therefore, treatment with BV could possibly be a safe and efficient strategy to prevent the development of allergic diseases in children.
在过去的十年中，哮喘的患病率稳步上升，这可能是由于环境变化的结果，包括婴儿期微生物暴露减少。因此，实验研究表明，故意感染活病原体可预防小鼠发生过敏性气道疾病。细菌提取物目前用于反复上呼吸道感染的儿童。在本研究中，我们研究了商业上可获得的细菌提取物 Broncho-Vaxom（BV）是否可预防小鼠的过敏性气道疾病。BV 的口服治疗通过白细胞介素-10（IL-10）依赖性和 MyD88（髓样分化初级反应基因 88）依赖性机制抑制气道炎症，并诱导 FoxP3（叉头框 P3）（-）T 细胞向 FoxP3（+）调节性 T 细胞转化。此外，从 BV 治疗的小鼠气管中纯化的 CD4（+）T 细胞在过继转移到致敏小鼠时可提供针对气道炎症的保护。因此，BV 治疗可能是预防儿童过敏性疾病发展的一种安全有效的策略。
